Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BJYDH
ADC Name
LMB-12
Synonyms
LMB 12; SS1-dsFv-LRggs
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
Antibody Name
Anti-MSLN scFv
  Antibody Info 
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Pseudomonas exotoxin PE24
  Payload Info 
Therapeutic Target
Eukaryotic elongation factor 2 (EEF2)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.17
ng/mL
KLM-1 cells
Pancreatic ductal adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.17 ng/mL±0.08 ng/mL Positive MSLN expression (MSLN +++/++)
Method Description
KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
In Vitro Model Pancreatic ductal adenocarcinoma KLM-1 cells CVCL_5146
References
Ref 1 Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.